Literature DB >> 31738865

Annual Immunisation Coverage Report 2017.

Brynley Hull1, Alexandra Hendry1, Aditi Dey1, Julia Brotherton2, Kristine Macartney1, Frank Beard1.   

Abstract

This eleventh national annual immunisation coverage report focuses on data for the calendar year 2017 derived from the Australian Immunisation Register (AIR) and the National Human Papillomavirus (HPV) Vaccination Program Register. This is the first report to include data on HPV vaccine course completion in Aboriginal and Torres Strait Islander (Indigenous) adolescents. 'Fully immunised' vaccination coverage in 2017 increased at the 12-month assessment age reaching 93.8% in December 2017, and at the 60-month assessment age reaching 94.5%. 'Fully immunised' coverage at the 24-month assessment age decreased slightly to 89.8% in December 2017, following amendment in December 2016 to require the fourth DTPa vaccine dose at 18 months. 'Fully immunised' coverage at 12 and 60 months of age in Indigenous children reached the highest ever recorded levels of 93.2% and 96.9% in December 2017. Catch-up vaccination activity for the second dose of measles-mumps-rubella-containing vaccine was considerably higher in 2017 for Indigenous compared to non-Indigenous adolescents aged 10-19 years (20.3% vs. 6.4%, respectively, of those who had not previously received that dose). In 2017, 80.2% of females and 75.9% of males aged 15 years had received a full course of three doses of human papillomavirus (HPV) vaccine. Of those who received dose one, 79% and 77% respectively of Indigenous girls and boys aged 15 years in 2017 completed three doses, compared to 91% and 90% of non-Indigenous girls and boys, respectively. A separate future report is planned to present adult AIR data and to assess completeness of reporting. © Commonwealth of Australia CC BY-NC-ND.

Entities:  

Keywords:  zzm321990 Indigenous immunisation coveragezzm321990 ; zzm321990 adolescent immunisation coveragezzm321990 ; zzm321990 human papillomavirus vaccine coveragezzm321990 ; zzm321990 immunisation coveragezzm321990 ; zzm321990 immunisation delayzzm321990 ; zzm321990 influenza vaccinationzzm321990

Mesh:

Substances:

Year:  2019        PMID: 31738865     DOI: 10.33321/cdi.2019.43.47

Source DB:  PubMed          Journal:  Commun Dis Intell (2018)        ISSN: 2209-6051


  6 in total

1.  Rotavirus Disease and Genotype Diversity in Older Children and Adults in Australia.

Authors:  Celeste M Donato; Susie Roczo-Farkas; Carl D Kirkwood; Graeme L Barnes; Julie E Bines
Journal:  J Infect Dis       Date:  2022-06-15       Impact factor: 7.759

2.  Sustained Vaccination Coverage during the Coronavirus Disease 2019 Epidemic in the Republic of Korea.

Authors:  Jeong Hee Yu; Hang Jin Jeong; Seon Ju Kim; Jae Young Lee; Young June Choe; Eun Hwa Choi; En Hi Cho
Journal:  Vaccines (Basel)       Date:  2020-12-22

3.  Cumulative annual coverage of meningococcal B vaccination in Australian general practice for three at-risk groups, 2014 to 2019.

Authors:  Juliana de Oliveira Costa; Christopher Gianacas; Frank Beard; David Gonzalez-Chica; Kendal Chidwick; Rawa Osman; C Raina MacIntyre; Alys Havard
Journal:  Hum Vaccin Immunother       Date:  2021-05-28       Impact factor: 4.526

4.  "No jab, no pay": catch-up vaccination activity during its first two years.

Authors:  Brynley P Hull; Frank H Beard; Alexandra J Hendry; Aditi Dey; Kristine Macartney
Journal:  Med J Aust       Date:  2020-09-19       Impact factor: 7.738

5.  Characterisation of a G2P[4] Rotavirus Outbreak in Western Australia, Predominantly Impacting Aboriginal Children.

Authors:  Celeste M Donato; Nevada Pingault; Elena Demosthenous; Susie Roczo-Farkas; Julie E Bines
Journal:  Pathogens       Date:  2021-03-16

6.  No Consistent Evidence of Decreased Exposure to Varicella-Zoster Virus Among Older Adults in Countries with Universal Varicella Vaccination.

Authors:  Stephane Carryn; Brigitte Cheuvart; Michael Povey; Alemnew F Dagnew; Rafael Harpaz; Robbert van der Most; Giacomo Casabona
Journal:  J Infect Dis       Date:  2022-02-01       Impact factor: 7.759

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.